Table 2. The recommended management of liver disease in UK clinical commissioning groups and health authorities in relation to national standards and guidelines

Area of UK	Using BSG-endorsed LFT pathwayn (%)	Using liver fibrosisassessmentn (%)	Using indirect serum fibrosis markers^an (%)	Using direct serum fibrosis markers^bn (%)	Using transientelastography^cn (%)
Englandn = 135	50 (37%)	52 (39%)	56 (41%)	18 (13%)	26 (19%)
Northern Irelandn = 5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Scotlandn = 12	8 (67%)	8 (67%)	9 (75%)	6 (50%)	7 (58%)
Walesn = 7	6 (86%)	7 (100%)	5 (71%)	2 (29%)	7 (100%)
UK totaln = 159	64 (40%)	67 (42%)	70 (44%)	26 (16%)	40 (25%)

^aIncluded use of Fib4 score, non-alcoholic fatty liver diease (NAFLD) fibrosis score and AST:ALT (aspartate aminotransferase: alanine aminotransferase) ratio (other options given); ^bAll but one response was for the enhanced liver fibrosis (ELF) test, single response hyaluronic acid.^cAll using FibroScan.
BSG = British Society of Gastroenterology. LFT = liver function test. n = number of commissioning bodies